Platelet-derived Growth Factor (pdgf) Or Derivative Patents (Class 514/8.2)
  • Patent number: 8444417
    Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: May 21, 2013
    Assignee: Stemnion, Inc.
    Inventors: William J. Golden, Randall G. Rupp
  • Publication number: 20130122095
    Abstract: The present invention provides compositions and methods for treating an osteochondral defect. In one embodiment, provided is a composition for treating an osteochondral defect comprising a biphasic biocompatible matrix and platelet derived growth factor (PDGF), wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase. In another embodiment, also provided is a method for treating an osteochondral defect in an individual comprising administering to the individual an effective amount of a composition comprising a biphasic biocompatible matrix and PDGF to at least one site of the osteochondral defect, wherein the biphasic biocompatible matrix comprises a scaffolding material and wherein the scaffolding material forms a porous structure comprising an osseous phase and a cartilage phase.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 16, 2013
    Applicant: BIOMIMETIC THERAPEUTICS, INC.
    Inventor: BIOMIMETIC THERAPEUTICS, INC.
  • Publication number: 20130115302
    Abstract: A polysaccharide micro-particle encapsulating a growth factor is disclosed and shall include one or more growth factors, and a polysaccharide shell forming a space to encapsulate the growth factor by electrostatic interaction. Also, a method for manufacturing a polysaccharide micro-particle encapsulating a growth factor is disclosed, which shall include the following process: (A) providing a pH 4.6-6 polysaccharide solution and a growth factor; and (B) adding the growth factor to the polysaccharide solution, and adjusting the polysaccharide solution to a pH of 6-8 to obtain the polysaccharide micro-particle encapsulating the growth factor by electrostatic interaction. According to the polysaccharide shell structure, the growth factor can be stored for a long period of time and heal skin wounds, mucositis, and corneal ulcer effectively.
    Type: Application
    Filed: April 4, 2012
    Publication date: May 9, 2013
    Applicant: MICORNA DERMAL THERAPY LAB CO., LTD.
    Inventor: Le Shin CHANG
  • Publication number: 20130108683
    Abstract: The present invention provides compositions and methods for treating deep partial thickness or full thickness wounds or injuries. The present invention also provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such partial thickness or full thickness wounds or injuries, as well as promoting vascularization and angiogenesis in regenerating and/or supportive tissue at such sites.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 2, 2013
    Applicant: BIOMIMETIC THERAPEUTICS, INC.
    Inventor: BioMimetic Therapeutics, Inc.
  • Publication number: 20130108670
    Abstract: The present invention provides compositions and methods for treating full thickness burn injuries. The present invention provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such a full thickness burn injury, as well as promoting vascularization and angiogenesis in regenerating tissue at such sites.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 2, 2013
    Applicant: BIOMIMETIC THERAPEUTICS, INC.
    Inventor: BioMimetic Therapeutics, Inc.
  • Patent number: 8431129
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: April 30, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Publication number: 20130095060
    Abstract: The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.
    Type: Application
    Filed: April 10, 2012
    Publication date: April 18, 2013
    Applicant: National Cheng Kung University
    Inventors: PATRICK C.H. HSIEH, YI-DONG LIN
  • Publication number: 20130085103
    Abstract: A synergistic pharmaceutical composition for the preparation of topical formulations for use in prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers, diabetic foot ulcers and other skin diseases is provided. The composition may include one or more synergistically active ingredients and one or more inactive ingredients. The synergistically active ingredients may include Recombinant Human Epidermal Growth Factor (rh-EGF) (REGEN-D™ of Bharat Biotech International Limited) and/or Platelet Derived Growth Factor (rh-PDGF-BB), silver sulfadiazine (SSD) and chlorhexidine gluconate (CHG). One or more inactive ingredients may comprise carriers, preservatives, emulsifiers, skin emollients and soothers and one or more other constituents.
    Type: Application
    Filed: July 14, 2010
    Publication date: April 4, 2013
    Applicant: BHARAT BIOTECH INTERNATIONAL LIMITED
    Inventors: Vadrevu Krishna Mohan, Venkata Charish Babu Pelluri, Khajesh Sharma
  • Publication number: 20130078224
    Abstract: The disclosure relates to the field of ischemia and how to increase tissue perfusion in ischemic tissue by cellular therapy. Specifically, the beneficial effects of myeloid (bone marrow-derived) cells with a particular arteriogenic gene expression profile are shown, and it is shown that increased arteriogenesis and perfusion is specifically due to the effects of combined PDGFB and SDF-1. The arteriogenic gene profile of the myeloid cells used for therapy can, for instance, be obtained by inhibition of PHD2.
    Type: Application
    Filed: March 30, 2011
    Publication date: March 28, 2013
    Applicants: LIFE SCIENCES RESEARCH PARTNERS VZW, VIB VZW
    Inventors: Massimiliano Mazzone, Peter Carmeliet
  • Publication number: 20130071457
    Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.
    Type: Application
    Filed: November 13, 2012
    Publication date: March 21, 2013
    Applicant: STEMNION, INC.
    Inventor: STEMNION, INC.
  • Patent number: 8399409
    Abstract: The present invention provides compositions and methods for facilitating fusion of bones in a joint. The present invention provides compositions and methods for promoting fusion of bones in arthrodetic procedures. In one embodiment, a method of performing an arthrodetic procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired bone fusion in a joint.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: March 19, 2013
    Assignee: BioMimetic Therapeutics Inc.
    Inventors: Samuel E. Lynch, Charles E. Hart
  • Publication number: 20130045918
    Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.
    Type: Application
    Filed: February 6, 2012
    Publication date: February 21, 2013
    Applicants: CALREGEN INC., NEW YORK UNIVERSITY
    Inventors: Leslie I. Gold, Marek Michalak
  • Patent number: 8377864
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Publication number: 20130028984
    Abstract: Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.
    Type: Application
    Filed: July 27, 2012
    Publication date: January 31, 2013
    Inventors: Hui Xu, Wenquan Sun, Hua Wan, Rick Owens
  • Patent number: 8361467
    Abstract: The present invention relates to trans-capsularly administering into a diseased joint a high specificity antagonist selected from the group consisting of: i) an inhibitor of a pro-inflammatory interleukin; ii) an inhibitor of TNF-? synthesis; iii) an inhibitor of membrane-bound TNF-?; iv) an inhibitor of a natural receptor of TNF-?; v) an inhibitor of NO synthase, vi) an inhibitor of PLA2 enzyme; vii) an anti-proliferative agent; viii) an anti-oxidant; ix) an apoptosis inhibitor selected from the group consisting of EPO mimetic peptides, EPO mimetibodies, IGF-I, IGF-II, and caspase inhibitors, and x) an inhibitor of MMPs; and xi) an inhibitor of p38 kinase.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: January 29, 2013
    Assignee: DePuy Spine, Inc.
    Inventors: Thomas M. DiMauro, Mohamed Attawia, Hassan Serhan, Martin A. Reynolds, Melissa Grace, Sudhakar Kadiyala, David Urbahns, Scott Bruder, Gregory Collins, Laura J. Brown, Jeff Geesin, Pamela L. Plouhar, Catherine Smith, John Siekierka
  • Publication number: 20130022661
    Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.
    Type: Application
    Filed: July 21, 2011
    Publication date: January 24, 2013
    Applicant: Warsaw Orthopedic, Inc.
    Inventor: William F. McKay
  • Patent number: 8357388
    Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: January 22, 2013
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: William F. McKay
  • Publication number: 20130017169
    Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.
    Type: Application
    Filed: March 2, 2011
    Publication date: January 17, 2013
    Applicant: PROTALIX LTD.
    Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
  • Patent number: 8349796
    Abstract: The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction.
    Type: Grant
    Filed: March 15, 2011
    Date of Patent: January 8, 2013
    Assignee: BioMimetic Therapeutics Inc.
    Inventors: Samuel E. Lynch, Charles E. Hart, Michael G. Ehrlich, Douglas C. Moore
  • Publication number: 20120321597
    Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.
    Type: Application
    Filed: August 31, 2012
    Publication date: December 20, 2012
    Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
  • Publication number: 20120316111
    Abstract: The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of one or more of the following compounds prazosin, quinacrine, emetine, apomorphine, and debrisoquine, whereby endogenous BMP-2 up-regulation is stimulated in said subject. The endogenous BMP-2 up-regulation may enhance bone formation and/or cartilage formation.
    Type: Application
    Filed: June 8, 2011
    Publication date: December 13, 2012
    Applicant: SOUTHWEST RESEARCH INSTITUTE
    Inventor: Jorge G. ROSSINI
  • Publication number: 20120316110
    Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.
    Type: Application
    Filed: March 26, 2012
    Publication date: December 13, 2012
    Applicant: Ben-Gurion University of the Negev
    Inventors: Smadar Cohen, Jonathan Leor
  • Patent number: 8318197
    Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: November 27, 2012
    Assignee: Stemnion, Inc.
    Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel
  • Patent number: 8318672
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: November 27, 2012
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
  • Patent number: 8318665
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: August 28, 2012
    Date of Patent: November 27, 2012
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S Marshall, Catherine J Trumpower, Charlotte A Smith
  • Patent number: 8313764
    Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: November 20, 2012
    Assignee: Stemnion, Inc.
    Inventors: David L. Steed, Linda O. Palladino
  • Patent number: 8298534
    Abstract: Materials and Methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 30, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Charles E. Hart, Stavros Topouzis, Debra G. Gilbertson
  • Patent number: 8283316
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: October 9, 2012
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
  • Patent number: 8282963
    Abstract: This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: October 9, 2012
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Mark T. Roedersheimer
  • Patent number: 8278417
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: April 10, 2012
    Date of Patent: October 2, 2012
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
  • Publication number: 20120244111
    Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.
    Type: Application
    Filed: June 11, 2012
    Publication date: September 27, 2012
    Applicant: Stem Cell Therapeutics Corp.
    Inventors: Samuel WEISS, Emeka ENWERE, Linda ANDERSEN, Christopher GREGG
  • Publication number: 20120237476
    Abstract: The present invention provides methods of forming a solid, biodegradable implant in-situ in a body by administering a liquid pharmaceutical composition comprising an effective amount of a biocompatible, water-insoluble, biodegradable polymer and an effective amount of a therapeutic peptide covalently modified with one or more lipophilic or amphiphilic moieties, which are dissolved or dispersed in a biocompatible, water-soluble organic solvent. This invention also provides related compositions and methods.
    Type: Application
    Filed: May 25, 2012
    Publication date: September 20, 2012
    Applicant: Foressee Pharmaceuticals, LLC
    Inventors: Yuhua LI, Benjamin CHIEN
  • Patent number: 8268362
    Abstract: The invention relates to a medicinal product for topical use for the promotion of wound healing, which comprises thrombocytes or thrombocyte fragments, wherein the thrombocytes or thrombocyte fragments contain growth factors and are capable of releasing the same and are present in the lyophilized or deep-frozen state and have been subjected to a process for virus partitioning and/or virus inactivation.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: September 18, 2012
    Assignee: Bio-Products & Bio-Engineering Aktiengesellschaft
    Inventors: Friedrich Braun, Hans Peter Spängler, Johann Eibl
  • Publication number: 20120230950
    Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.
    Type: Application
    Filed: May 21, 2012
    Publication date: September 13, 2012
    Applicant: Humacyte, Inc.
    Inventors: Laura Niklason, Yuling Li, Juliana Blum, Shannon Dahl, Geoffrey Erickson, Frank Zeigler
  • Publication number: 20120225114
    Abstract: The present invention provides compositions and methods for modulating one or more phenotypes of a macrophage-related cell, e.g., a macrophage. The invention further provides methods of treating disease by modulating macrophage phenotype. Representative phenotypes include pro-inflammatory, anti-inflammatory, immunogenic, tolerogenic, tissue-destructive, tissue restorative, cytotoxic, migratory, bone-resorbing, pro-angiogenic, anti-angiogenic, suppressor, antigen presentation, or phagocytic. Representative diseases include atherosclerosis, arthritis, and multiple sclerosis.
    Type: Application
    Filed: December 1, 2011
    Publication date: September 6, 2012
    Applicant: APELLIS PHARMACEUTICALS, INC.
    Inventors: Cedric Francois, Pascal Deschatelets, Paul Olson
  • Publication number: 20120195939
    Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.
    Type: Application
    Filed: March 20, 2012
    Publication date: August 2, 2012
    Inventor: Bernardo Nadal-Ginard
  • Publication number: 20120189669
    Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.
    Type: Application
    Filed: May 23, 2010
    Publication date: July 26, 2012
    Applicant: CARTIHEAL (2009) LTD.
    Inventors: Nir Altschuler, Razi Vago
  • Publication number: 20120183585
    Abstract: The various embodiments herein provide a gel based wound dressing comprising a lyophilized powder and a water-based solvent. The lyophilized powder comprises several nanoparticles and water miscible natural or synthetic polymers. The nanoparticles comprises pectin and a wound healing agent or an anti-microbial agent. The anti-microbial agent is nisin. The lyophilized powder and the water-based solvent are kept in two separate sealed packages and are mixed together before applying on a wound. The embodiments herein also provide a method of synthesizing the gel based wound dressing. The nano-particles control a release of the wound healing agent or the antimicrobial agent to a wound.
    Type: Application
    Filed: February 25, 2012
    Publication date: July 19, 2012
    Inventors: Rassoul Dinarvand, Nasrin Samadi, Azade Taheri Borujeni
  • Publication number: 20120177702
    Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.
    Type: Application
    Filed: May 23, 2010
    Publication date: July 12, 2012
    Applicant: CARTIHEAL (2009) LTD.
    Inventors: Nir Altschuler, Razi Vago
  • Publication number: 20120171257
    Abstract: Disclosed are methods for producing cell-guiding fibroinductive and angiogenic tissue engineering scaffolds composed of biodegradable and biocompatible natural biopolymers, synthetic polymers and/or their combination, incorporating growth and differentiation factors, growth hormone and chemoattractants, with interconnected pores and channels-containing microarchitecture inducing the regenerative cell migration, adhesion, proliferation and differentiation from the healthy tissues surrounding the periodontal defects, thereby facilitating the functional periodontal tissue regeneration. The methods for the application of the cell-guiding fibroinductive and angiogenic scaffolds in the surgical treatment of periodontal tissue defects resulted from destructive periodontal diseases are also provided.
    Type: Application
    Filed: September 12, 2009
    Publication date: July 5, 2012
    Inventors: Bülend Inanç, Levent Inanç
  • Publication number: 20120156306
    Abstract: The invention relates to a viral-safe platelet extract, to its preparation and use. The extract comprises a mixture of biologically active platelet derived factors. Advantageously, the extract comprises a balanced proportion of the factors and is non-clottable.
    Type: Application
    Filed: December 20, 2011
    Publication date: June 21, 2012
    Inventors: Lior Weissman, Nina Raver-Shapira, Israel Nur, Oleg Belyaev
  • Publication number: 20120156164
    Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.
    Type: Application
    Filed: September 2, 2010
    Publication date: June 21, 2012
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Ki-Dong Park, Yoon-ki Joung, Kyung-Min Park, Eu-Gene Lih
  • Publication number: 20120148529
    Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.
    Type: Application
    Filed: May 12, 2010
    Publication date: June 14, 2012
    Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.
    Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
  • Patent number: 8198239
    Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: June 12, 2012
    Assignee: Stemnion, Inc.
    Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
  • Publication number: 20120141555
    Abstract: The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.
    Type: Application
    Filed: January 24, 2012
    Publication date: June 7, 2012
    Inventor: Arne Briest
  • Publication number: 20120141410
    Abstract: Embodiments of the invention relate to compositions and methods of dry eye or keratoconjunctivitis sicca.
    Type: Application
    Filed: September 12, 2011
    Publication date: June 7, 2012
    Applicant: INVITRX, INC.
    Inventor: Habib Torfi
  • Publication number: 20120141558
    Abstract: Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning.
    Type: Application
    Filed: February 9, 2012
    Publication date: June 7, 2012
    Applicant: UNIVERSITY OF WASHINGTON
    Inventors: Miqin Zhang, Narayan Bhattarai
  • Publication number: 20120130435
    Abstract: The present invention provides compositions and methods for facilitating fusion of bones in a joint. The present invention provides compositions and methods for promoting fusion of bones in arthrodetic procedures. In one embodiment, a method of performing an arthrodetic procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired bone fusion in a joint.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 24, 2012
    Applicant: BIOMIMETIC THERAPEUTICS, INC.
    Inventors: Charles E. HART, Samuel E. LYNCH
  • Publication number: 20120128774
    Abstract: The present invention provides effective new methods and materials for maxillofacial bone augmentation, particularly alveolar ridge augmentation, that are free of problems associated with prior art methods. In one embodiment, these materials include human recombinant platelet derived growth factor (rhPDGF-BB) and a biocompatible matrix. In another embodiment, these materials include rhPDGF-BB, a deproteinized bone block or calcium phosphate, and a bioresorbable membrane. The use of these materials in the present method is effective in regenerating maxillofacial bones and facilitating achievement of stable osseointegrated implants. The mandible and maxilla are preferred bones for augmentation, and enhancement of the alveolar ridge is a preferred embodiment of the present invention.
    Type: Application
    Filed: January 5, 2012
    Publication date: May 24, 2012
    Applicant: BIOMIMETIC THERAPEUTICS, INC.
    Inventors: Samuel E. Lynch, Myron Nevins, Massimo Simion
  • Publication number: 20120100103
    Abstract: Disclosed are in situ-forming injectable hydrogel and medical uses thereof. In the in situ-forming injectable hydrogel two or more homogeneous or heterogeneous polymers are bonded to each other by a dehydrogenation reaction between phenol or aniline moieties on adjacent polymers, wherein a polymer backbone is grafted with a phenol or aniline moiety using a linker. In contrast to conventional hydrogel, the in situ-forming injectable hydrogel is superior in terms of in vivo stability and mechanical strength thanks to the introduction of a water-soluble polymer as a linker which leads to an improvement in the reactivity of phenol or aniline moieties. Having the advantage of superior bio stability and mechanical strength, the hydrogel finds a variety of applications in the biomedical field.
    Type: Application
    Filed: July 1, 2010
    Publication date: April 26, 2012
    Inventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park